Objective: The radial artery is increasingly used for coronary artery bypass grafts, but its potential for spasm increases postoperative risk. Alpha-calcitonin gene-related peptide is a potent antihypertensive peptide.
R adial arteries are being used more frequently as coronary artery bypass grafts. However, radial arteries are prone to spasm and thus increase the risk of graft failure. 1 Angiotensin II (ang II) is an active component of the renin-angiotensin system, which, through its receptor (AT1R), plays an important role in the control of vasoconstriction, cell growth and apoptosis, cell migration, and extracelluar matrix deposition, events that are involved in cardiovascular disease. 2 On the other hand, calcitonin gene-related peptide (CGRP) is an inhibitor of cell growth and a potent endothelium-independent vasodilator, [3] [4] [5] thus suggesting that it could inhibit ang II-mediated effects. Indeed, long-term ang II infusion is accompanied by an increase in CGRP receptor expression in mesenteric arteries but not in CGRP levels in plasma. 6 aCGRP is a 37-amino acid peptide, produced by tissue-specific alternative splicing of the primary transcript of the calcitonin/aCGRP gene. 7 A second CGRP isoform, ßCGRP, is encoded by a different gene locus and is localized almost exclusively to specific neuronal sites. 8 These two CGRP isoforms-a and b in rats and I and II in humans-exhibit overlapping biological activities in most vascular beds, 9 but aCGRP appears to be regulated by nitric oxide (NO). 10 CGRP has complex cardiovascular actions. For example, the intramuscular gene transfer of CGRP inhibits neointimal hyperplasia after balloon injury in the rat abdominal aorta, 11 possibly by 
Abbreviations and Acronyms
ang II 5 angiotension II CGRP 5 calcitonin gene-related peptide EDHF 5 endothelium-dependent hyperpolarization L-NAME 5 N-nitro-L-arginine methyl ester NO 5 nitric oxide affecting the NO system 10, 11 and the proliferation of vascular smooth muscle cells induced by fetal bovine serum. 12 More important, CGRP can act directly on smooth muscle cells and stimulate relaxation independently of endothelial function in porcine coronary arteries. 3 Inasmuch as CGRP can induce vasorelaxation independently of endothelial function and CGRP appears to counteract ang II vasoconstriction in animal models, we sought to determine whether such effects extend to human arteries. To this end, we have used human radial arteries with impaired endothelial function to test the direct effects of CGRP on ang II-mediated vasoconstriction.
Methods
Discarded distal segments of radial arteries 13 were obtained from 25 patients undergoing coronary artery bypass grafting using the ''open'' technique for harvesting. Patients aged 48 to 70 years gave informed consent and were receiving 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, angiotensin-converting enzyme inhibitors, nitrates, and beta adreno-receptor blockers. Patients receiving angiotensin receptor blockers were excluded from this study. Only nontraumatized vessel segments were used in this study. This study was approved by the Austin Hospital Medical Research Ethics Committee and followed institutional guidelines. Harvesting was performed by techniques previously established in our operating theaters 1 ; in particular, the specimens were obtained after intraluminal hydrostatic dilatation with papaverine, which impairs endothelial function.
Isometric Tension Studies
Blood vessels were cleaned of connective tissue and fat and stored at 4 C overnight. Pilot studies in our laboratory show no difference in vessel function between freshly isolated radial artery rings and those kept in overnight 4 C storage, as also described elsewhere.
14 Vessels were then cut into 3-mm rings and sequentially mounted between two metal hooks in organ baths attached to force displacement transducers (Grass FT03; Grass Instrument Co, Quincy, Mass). The baths were filled with Krebs solution, kept at a constant temperature of 37 C, and continuously bubbled with 95% oxygen/5% carbon dioxide. After a 2-hour equilibration period, the rings were stretched to their optimized tension. This technique allows normalization of vascular rings to a physiologic pressure in vitro compared with in vivo and is the accepted method for isometric tension studies. 15 ). The vessel equilibration time also served to minimize the effect of patient therapy on vessels. 18 All experimental data were normalized to control, which was set at 100%.
To determine the influence of potassium channels or NO on the inhibitory effects of CGRP, N-nitro-L-arginine methyl ester (L-NAME; 10 25 mol/L, to inhibit NO), 4-aminopyridine (3 mmol/L, to inhibit voltage-dependent K 1 channels), charybdotoxin and apamin (50 3 10 29 mol/L and 3 3 10 27 mol/L, respectively), to inhibit endothelium-dependent hyperpolarization (EDHF), and calcium-activated K 1 channels and 10 24 mol/L barium chloride (to inhibit inwardly rectifying K 1 channels) where used. These concentrations have been shown to be specific for each potassium channel. 19, 20 Data Analysis Data are presented as mean 6 standard error of the mean, where ''n'' represents the number of independent samples studied. Data from arterial samples are expressed as percent response to 124 mmol/L KCl. Statistical comparisons were undertaken with either the Student t test or a 1-way analysis of variance (where appropriate) and a P value of .05 using GraphPad Prism software (GraphPad Software, Inc, San Diego, Calif). 26 mol/L by 22% (P , .01) (Figure 1, A) . There was no difference in maximum contraction evoked by 124 mmol/L potassium between groups (Figure 1, B) .
Results

Effects of aCGRP
Effects of aCGRP on Basal Tone aCGRP also significantly decreased basal vascular tension in human radial arteries. After the 20-minute period following the addition of aCGRP or vehicle (control), 10 27 mol/L aCGRP showed the highest decrease in basal tension (expressed as force in grams, Figure 1 Effects of L-NAME on aCGRP-induced Vasodilation To determine whether NO release was involved in the effects of CGRP, we added L-NAME to the organ baths 20 minutes before the ang II dose response curve. Then, at 10 28 mol/L (ang II), aCGRP (10 28 mol/L) was added and aCGRP completely relaxed arteries after approximately 10 minutes. The actual trace is shown in Figure 2 , A, and the results of 3 independent experiments are shown in Figure 2 , B.
Effects of aCGRP on Potassium Channels
To determine whether potassium channels were involved in the effects of aCGRP, we added 4-aminopyridine to the radial artery and vasoconstriction occurred rapidly, an effect that was completely reversed by the addition of 10 28 mol/L aCGRP but restored by the addition of ba 21 (actual trace shown, Figure 2, C) ; the results of 5 independent experiments are shown in Figure 2 , D. As well, charybdotoxin plus apamin ( Figure 2, E and F) ) was added to radial arteries to inhibit endothelium hyperpolarization via the release of EDHF and calcium-activated K 1 channels. This had no effect on 10 
Discussion
This study clearly establishes the importance of aCGRP in influencing radial artery basal tone and desensitizing it to the vasoconstrictive effects of ang II. Furthermore, it was demonstrated that aCGRP-induced vasodilation is preserved in the presence of L-NAME, an NO synthase inhibitor, suggesting that aCGRP is not dependent on NO for its activity, but could be associated with opening the Kir potassium channel. We further propose that aCGRP at a concentration of 10 nmol/L could be used in preoperative radial artery bath preparations to impair vasospasm and improve postoperative risk.
Growing evidence is indicating that aCGRP and ang II may act reciprocally to help maintain circulatory homeostasis. [21] [22] [23] [24] [25] Our results support this hypothesis, indicating that CGRP acts as a functional antagonist of ang II-mediated vasoconstriction and attenuates vasoconstriction in a dosedependent manner. This result is consistent with previous rat model investigations, which found that CGRP inhibits ang II-induced vasoconstriction. 21, 22 Indeed, the only other comparable study involving human radial arteries also yielded similar results. mol/L (n 5 9), inhibition of angiotensin II remained constant at 68% and 69%, respectively, and did not follow the dose-dependent increase observed for lower concentrations (P < .001 in both cases). B, Box plots showing the maximum potassium (K 1 ) constriction per CGRP dose tested. Each experimental dose (closed box) was normalized to its adjacent segment (control, open box), as to restrict variation between segments. There was no difference in the maximum contraction to 124 mmol/ L potassium in any group. C, Exposing human radial arteries to increasing concentrations of CGRP has a dose-dependent, albeit slight, dilatory effect on the basal arterial tone of isolated human radial arteries over a 20-minute period. Results are mean 6 SEM, *P < .05, **P < .01, yP < .001.
Altered vascular K
1 channel function in cardiovascular disease could be either a cause or consequence of the disease. A current review by Sobey 20 clearly describes the role of K 1 channels in cardiovascular disease. Nevertheless, studies have indicated that current medications used in the treatment of hypertension may already inadvertently involve CGRP and thus open K 1 channels. Qin and associates 27 demonstrated that the depressor effects of losartan (ang II receptor antagonist) and perindopril (angiotensin-converting enzyme inhibitor) may be partially mediated via increased synthesis and release of CGRP. Furthermore, the antihypertensive effect of the novel drug rutaercarpine may also be mediated by stimulation of CGRP synthesis and release. 28 Rutaecarpine is a quinazolinocarboline alkaloid isolated from a widely known Chinese herbal drug Wu-chu-yu. In animal models, its mode of action is suggested to be via stimulating endogenous CGRP release via activation of vanilloid receptor subtype 1. 28, 29 Whether rutaecarpine causes similar effects as CGRP in human radial arteries is the focus of ongoing studies.
The precise mechanisms that regulate the expression and release of CGRP are unknown. However, several different classes of regulatory factors act to modulate CGRP synthesis and release by antagonizing or activating nerve growth factor. 30 As CGRP is released directly onto the smooth muscle cell layer from the innervation into the wall, the physiologic concentration of CGRP at the site of action is many times greater than the picomolar plasma concentration observed in healthy human volunteers. 31 It is generally considered that the levels of CGRP detected in plasma are likely to be due to leakage after localized release rather than a specific systemic function. As well, although CGRP is widely established as a potent vasodilator, its exact mechanism of action remains unclear. There are currently two modes of action, endothelium dependent and endothelium independent. 32 The endothelium-dependent pathway suggests that CGRP activity is mediated via the production of endothelial NO, which then relaxes vascular smooth muscle cells. 32 The endothelium-independent pathway proposes that CGRP directly 25 mol/L L-NAME. CGRP potently restores normal basal tension after approximately 10 minutes, indicating no effect of nitric oxide on CGRP-induced vasodilation. B, Tabulated results of 3 independent experiments. C, 4-Aminopyridine (4-Ap) was used to block voltage-dependent K 1 channels, and vasoconstriction occurred immediately after the addition of the drug. CGRP was able to restore basal tension within minutes, binds to receptors on the smooth muscle cells and is coupled to production of cyclic adenosine monophosphate by adenylate cyclase. The increase in intracellular cyclic adenosine monophosphate concentration stimulates protein kinase A, and this opens K 1 channels and activates calcium sequestration mechanisms to cause smooth muscle cell relaxation. 32 The majority of data from studies involving rat, human, and porcine tissues suggest that CGRP can cause vasodilation in the absence of an endothelium, thereby supporting the role of an endothelium-independent pathway. 32, 33 Conversely, studies have also shown that NO synthase inhibitor blocks CGRP activity in the rat aorta, rat pulmonary artery, and human internal thoracic artery, suggesting CGRP-mediated vasodilation is dependent on the presence of NO and therefore the endothelium. [34] [35] [36] In our study, blocking NO synthesis with L-NAME, a NO synthase inhibitor, did not affect CGRP-induced vasodilation, suggesting that CGRP is able to act via a pathway independent of the endothelium or NO. Therefore, this result supports the notion that in human radial arteries, CGRP activity might be mediated by an endothelium-independent pathway. It is difficult to speculate as to why the internal thoracic artery and radial artery respond differently to CGRP, although it could be associated with the increased wall thickness and intimal thickening of radial arteries. 1 However, we show clear evidence that CGRP can induce vasodilation in the presence of calcium-activated K 1 channel blockade, voltage-dependent K 1 channel blockade, but not with inwardly rectifying K 1 channel blockade (Kir), suggesting that a possible mechanism of action for CGRP is by opening the Kir channel. Our data suggest that the development of potassium channel openers could be a new avenue for the treatment of radial arteries before bypass surgery to impair spasm and lessen postoperative risk. Furthermore, the radial arteries used in this study did not respond to acetylcholine-mediated vasodilation (results not shown), indicating that a functional endothelium is not necessary for CGRP function.
In conclusion, this study has demonstrated that CGRP decreased the basal arterial tone in human radial arteries and, when challenged with ang II, CGRP significantly inhibited ang II-induced vasoconstriction in a dose-dependent manner. Inhibition of the Kir channel completely impaired the effects of CGRP, indicating an endothelium-independent mechanism for the actions of CGRP and is thus possibly more effective in diseased human vessels with underlying endothelial dysfunction.
